AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)
Description: Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: Medical Records Review
Description: Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
Study NCT03641807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
Study NCT03641807 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
Study NCT02645565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
Study NCT02645565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: azathioprine will be given at 2 mg/kg.
Study NCT02645565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
Study NCT00082368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tariquidar
Description: 3 days after initial PET patients will receive tariquidar and repeat imaging.
Study NCT00082368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-94m Sestamibi
Description: Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
Study NCT00107900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Study NCT02147197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: UPA tablet
Study NCT03119922 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01478386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Orthovisc
Description: Subjects will receive a series of three Orthovisc injections into their affected knee
Study NCT02147197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet.
Study NCT02147197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study NCT02764515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kunxian Capsule
Description: Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
Study NCT03605225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile cellphone application test
Description: Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
Study NCT02764515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
Study NCT00801632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation
Description: Surgical transplantation of donor kidney
Study NCT01478386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DonJoy HA lite knee brace
Description: Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
Study NCT01478386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthovisc injections and DonJoy HA lite knee brace
Description: Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
Study NCT03839823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel / Capecitabine
Description: Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)
Study NCT03839823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine / Vinorelbine
Description: Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]
Study NCT03839823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel / Gemcitabine
Description: Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)
Study NCT03839823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
Study NCT00206986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
Study NCT00206986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 0.15 mg of clonidine will be administered to 20 healthy male volunteers
Study NCT01078285 — intervention group
Intervention type: BEHAVIORAL
Intervention: No Patient Counseling
Description: Patients do not receive any adherence counseling, or other patient support services
Study NCT00801632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
Study NCT00801632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
Study NCT00801632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg infusion on days -5, -4
Study NCT00801632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 infusion on days -7, -2, 5, and 12
Study NCT01700959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
Study NCT01700959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets to match the melatonin will be comprised of inert substances.
Study NCT00801632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
Study NCT00801632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
Study NCT00801632 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thymic irradiation
Description: 700 cGy of thymic irradiation administered in a single dose on day -1
Study NCT03146559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG and TENS
Description: Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
Study NCT03146559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS only
Description: Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
Study NCT03698578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combat fight
Description: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
Study NCT01762774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
Study NCT01078285 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adherence Counseling
Description: Patients receive 3-5 minutes of adherence counseling, and other patient support services
Study NCT02422615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
Study NCT02422615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
Study NCT04717115 — intervention group
Intervention type: GENETIC
Intervention: Genetic diagnosis
Description: No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
Study NCT02695498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief.
Study NCT02695498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine/stress Education
Description: The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
Study NCT04578431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)
Description: The intervention is found in light products ingested by millions of people on a daily basis worldwide
Study NCT00495183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
Study NCT00495183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: Biperiden 2-4 mg/d, divided in 2 doses per day.
Study NCT00495183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04686071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF method
Description: Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
Study NCT01762774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
Study NCT02422615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
Study NCT02422615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
Study NCT00990808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: \[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
Study NCT00990808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
Study NCT00990808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to MK0859
Description: Placebo to MK0859 once daily for 4 weeks.
Study NCT00990808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to atorvastatin
Description: Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
Study NCT03839823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole OR Anastrozole
Description: Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician.
Study NCT03839823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant
Study NCT03275714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone APP
Description: Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
Study NCT04386486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bathe anamnesis method
Description: BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
Study NCT04386486 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standart anamnesis
Description: standart anamnesis is applied to second group and preoperative examinations are completed.
Study NCT03605225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile cellphone application test
Description: Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
Study NCT03050307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT03050307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT03050307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets
Study NCT03050307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study NCT03050307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study NCT02812615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg
Description: After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
Study NCT02812615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
Study NCT02812615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole/Pyrantel Pamoate
Description: As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
Study NCT02812615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Parents/caregivers will be given nutritional counselling
Study NCT02812615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles
Description: For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
Study NCT04476615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (ProLon®)
Description: Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
Study NCT04476615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bars
Description: Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Upper Extremity Function
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain intensity
Study NCT01036724 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Mapping
Description: Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT01222117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS depression
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive affect negative affect scale (PANAS)
Study NCT01222117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasminogen Activator
Description: Plasminogen activator used according to the Investigator's clinical judgment.
Study NCT04686071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard rehabilitation
Description: In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
Study NCT02590081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5%
Study NCT02590081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Study NCT04873804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Study NCT01222117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for injection at the same volume as the plasminogen activator.
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard PCS
Study NCT02209259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positively-adjusted version of the PCS